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Tissue-type plasminogen activator (t-PA) from human melanoma cells (Bowes) was purified by immunosorbent chroma- 
tography on affinospecific polyclonal antibodies and gel filtration in the presence of KSCN. The immunosorbent eluate 
contained three major components of >200, 85 and 65 kDa, respectively. The 65 kDa t-PA component could be sepa- 
rated by gel filtration on Ultrogel AcA44 in the presence of KSCN to a pure preparation yielding a unique N-terminal 
amino acid sequence. Immunoblot analysis, using affinospecific antibodies against t-PA, was a specific and sensitive 
method to identify different types of t-PA (I-IV), as well as t-PA-inhibitor complexes and degradation products in unstim- 
ulated melanoma cell culture fluids. Furthermore, the t-PA preparations, produced by phorbol ester-treated melanoma 
cells, were free of type IV and thus differed physicochemically from the constitutively produced t-PA preparations. The 
composition of t-PA from mammalian cell cultures is thus more complex than hitherto described. 
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1. INTRODUCTION 
Plasminogen activators are serine proteases, 
which are involved in various physiological and 
pathological processes, which require the degrada- 
tion of macromolecules: fibrinolysis, tissue- 
remodelling and cell migration in organogenesis, 
inflammation and perhaps also in malignant inva- 
sion and metastasis [1,2]. In the human species 
there exist at least two major different types of 
plasminogen activators: urokinase (u-PA) [3] and 
tissue-type plasminogen activator (t-PA) [4]. They 
are the products of different but related, spliced, 
single-copy genes located on the human 
chromosomes 10 and 8, respectively [5--g]. 
Because of its potential use in the therapy ef 
thromboembolic diseases, t-PA has recently re- 
ceived much attention both in fundamental and 
applied studies [9- 121. Several studies indicate that 
not only the polypeptide structure, but also the 
carbohydrate chains might influence the specific 
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activities of t-PA molecules [ 13- 151. Interactions 
of t-PA with specific inhibitors [16,17] and fibrin 
[18] have been described. 
After the initial purification of t-PA from 
uterine tissue [ 191, the human melanoma cell line 
(Bowes) has been widely used to purify t-PA by af- 
finity chromatography on Zn-chelate and Con A- 
Sepharose [20], on polyclonal [2 l] and monoclonal 
[22] antibodies and on specific inhibitors such as 
the trypsin inhibitor of Erythrina latissima [23]. 
The same cell line has originally been used to 
isolate t-PA mRNA [24] for cDNA cloning ex- 
periments [4,25-291. The complete gene as well as 
its flanking regions have been sequenced [30]. 
Several types of heterogeneity have been de- 
scribed for t-PA: single- and two-chain forms, N- 
terminus sequence heterogeneity seemingly 
associated with a microheterogeneity in protein se- 
quence [31], and glycosylation pattern differences, 
resulting in the appearance of type I and II 
variants, separable by SDS-PAGE [14]. 
In the present study we used Western-blot 
analysis to show the existence of at least 2 addi- 
tional types (III and IV) of t-PA in the culture 
fluids of a human melanoma cell line and to il- 
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lustrate that the relative amounts of these different 
types can change under specific culture conditions. 
2. MATERIALS AND METHODS 
2.1, Cell culture 
The human melanoma cell line (Bowes, RPM1 7272) was 
made mycoplasm-free by inoculation in nude mice and transfer 
of cells from the three-week solid tumor to in vitro culture. The 
cells were propagated and treated with the tumor promoting 
phorbol-myristate-acetate as described before [32-341. Cell 
culture fluids were collected as serum-free medium containing 
25 kallikrein-inhibitory units of aprotinin per ml. 
2.2. Preparation of affinospecific antibodies against human 
melanoma t-PA 
Melanoma t-PA was purified to homogeneity as described 
[20]. Polyclonal antibodies were raised in rabbits by repeated 
injections of 10 pg of t-PA, emulsified in complete Freund’s ad- 
juvant. Then booster injections were given at two week inter- 
vals. One week after the 5th booster 20 ml of peripheral blood 
was isolated. The immunoglobulin fraction was precipitated 
with ammonium sulphate and the IgG fraction was isolated by 
affinity chromatography on protein A-Sepharose (Pharmacia). 
Electrophoretically pure t-PA (200/g) was immobilized to 
CNBr-activated Sepharose CL-4C (Pharmacia). The IgG 
preparations were then affinity-purified and finally neutralized 
and concentrated by dialysis against 20 mM phosphate buffer, 
pH 7.2, 0.5 M NaCl, 5% polyethyleneglycol. 
2.3. Purification of t-PA by immunosorbent and gel-filtration 
chromatography 
Affinospecific antibodies against t-PA (2.5 mg) were coupled 
to CNBr-activated Sepharose CL-4B. The gel was equilibrated 
with phosphate buffered saline, supplemented with 2 M NaCl, 
0.01% Tween 80, and 25 units of aprotinin per ml. Approx. 
500 ml of serum-free melanoma culture fluid was 
chromatographed. The column was sequentially washed with 
the equilibration buffer: 1 M NaCl, 0.1 M glycine, NaOH, pH 
9.5, and 20 mM phosphate buffer, pH 7.2. The t-PA was 
desorbed with 3.5 M KSCN. All fractions containing 
amidolytic activity were concentrated by dialysis and applied to 
Ultrogel AcA44, equilibrated with 20 mM phosphate buffer, 
pH 7.2, 1.6 M KSCN. 
2.4. Protein determination, amidolytic assays, fibrin agar 
zymography, and amino acid sequence analysis 
Protein concentration was measured as described [35] using 
bovine serum albumin as a protein standard. Amidolytic ac- 
tivities were determined with a sensitive automated 
micromethod and expressed as described [13]. Zymography of 
plasminogen activators was as described (361. The N-terminal 
sequence of purified unmodified t-PA was determined with a 
477A sequenator with on-line detection of the PTH residues in 
a 120A analyser (Applied Biosystems Inc.). 
2.5. Electrophoresis and immunoblot analysis 
Protein samples were separated in vertical polyacrylamide 
slab gels in the presence of 0.1% SDS [37]. Fixed proteins in the 
gels were stained with Coomassie brilliant blue. For im- 
munoblot analysis, electrophoretically separated proteins were 
transferred onto nitrocellulose membranes, using a semi-dry 
electroblot apparatus (Jancos, Denmark) [38]. After overnight 
reaction of the membrane-bound proteins with the af- 
finospecific anti-t-PA antibodies, the membranes were exten- 
sively washed and then exposed to pig, peroxidase-labelled, 
anti-rabbit IgGs (Dakopatts, Denmark). Finally the membranes 
were washed and reacted with Hz02. 
3. RESULTS 
3.1. Purification of t-PA 
Approx. 500 ml of serum-free culture fluid from 
unstimulated or phorbol ester-treated melanoma 
cells was subjected to affinity chromatography on 
affinospecific antibodies directed against t-PA. 
Desorption of the bound molecules was monitored 
by electrophoretic analysis under reducing condi- 
tions and protein staining. Three major protein 
bands with apparent A4 values of > 200000, 85 000 
and 65000, respectively, were visualized in the 
eluted fractions, which contained most of the total 
applied amidolytic activity. The enzymatically ac- 
tive fractions of the immunosorbent column were 
pooled, concentrated and subjected to gel filtra- 
tion. Two major peaks were obtained of which on- 
ly the second contained amidolytic activity. 
Analysis by SDS-PAGE under non-reducing con- 
ditions and protein visualization by Coomassie 
blue staining showed the presence of two not 
sharply delineated bands (t-PA types I and II, ar- 
rowheads fig. 1, migrating close to each other in the 
65-70 kDa region) in the fraction containing the 
amidolytic activity and comigrating with bovine 
serum albumin. Zymographic analysis by the 
fibrin agar overlay technique showed that these 
protein bands coincided with the fibrinolytic ac- 
tivity (fig.1). A urokinase control sample showed 
on zymography, as expected, the presence of two 
proteins with plasminogen activating properties 
(55 kDa and an autocatalytical cleavage product of 
33 kDa). This urokinase sample appeared as a 
single protein band of 55 kDa after SDS-PAGE 
and staining. The appearance of the lysis zones was 
dependent on the presence of plasminogen (not 
shown). The overall yields and the purification fac- 
tors of the two-step purification method are sum- 
marized in table 1. Approx. 10 pug of the purified 
product was subjected to sequential degradation in 
a protein microsequencer. The unique sequence 
obtained was Ser-Tyr-Gln-Val-Ile-Xaa-Arg-Asp- 
Glu-Lys . . . This sequence is identical with that 
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staining zymography 
u-PA t-PA t-PA u-PA Mr 
~lg. 1. Analysis ot purlfled t-PA. ‘I’he purihed t-PA (10 pg) ana 
a control sample of u-PA were subjected to SDS-PAGE and the 
proteins were visualized by Coomassie brilliant blue staining 
(left). Samples both of t-PA and u-PA were run in parallel and 
after separation the plasminogen activators were developed by 
fibrin agar zymography in the presence of plasminogen (right). 
Arrowheads indicate the doublet types I and II of t-PA. 
Apparent molecular masses are indicated in kDa. 
previously described for the N-terminus of t-PA, 
where the Xaa position corresponds to a cysteine 
residue, not detectable in unmodified samples. 
This analysis furthermore corroborates that the 
obtained product is not contaminated with other 
N-terminal unblocked proteins. 
3.2. Immunoblot analysis 
Batches of 500 ml serum-free culture super- 
natants from melanoma cells, treated with 
100 ng/ml of phorbol ester or from untreated cells 
Table 1 
Purification of human t-PA from melanoma cells 
Purification Total amount of Yieldb Purifica- 
step proteina (%) tion factor 
olg) (@Jo) 
Culture medium 20100c 100 - 1 
Immunosorbent 138 0.81 73 106 
Ultrogel AcA44 85 0.49 65 151 
a The total amount of protein from 450 ml culture fluid was 
determined by the Bradford protein assay using BSA as a 
reference protein 
b Recovery yields as determined by the chromogenic substrate 
release assay 
’ Each individual value is the mean of three independent 
experiments with 450 ml culture fluid (SE < 10%) 
were purified as described and analyzed by 
Western-blot analysis using the affinity-purified 
polyclonal antibody. Surprisingly, cell culture 
fluids from unstimulated Bowes melanoma cells 
contained not only types I and II, that have been 
previously described, but also two additional t-PA 
species, henceforth called types III and IV. These 
new types of t-PA, when compared to types I and 
II, migrated faster and occurred as a less intense 
doublet with an apparent M, of about 60000. 
Types I-IV were reproducibly observed in our, as 
well as. in other preparations of t-PA (fig.2). 
Moreover the described Western-blot technique 
was useful to detect t-PA-inhibitor complexes and 
degradation products. Such complexes have 
previously been described to be resistant to 
dissociation under the used conditions of analysis 
[ 161. The immublot technique is a specific and sen- 
sitive assay for t-PA in that samples containing less 
than 10 ng of t-PA yielded the 4 different types. 
Direct protein visualization by Coomassie blue 
staining is not suited to detect these minor variants 
and is at least 100 times less sensitive than Western 
blot analysis [14]. With the use of our affinity- 
purified antiserum we were able to show a hitherto 
A B C 0 
Fig.2. Immunoblot analysis of t-PA preparations. Nanogram 
quantities of melanoma cell t-PA, purified as described in 
section 2 were separated by SDS-PAGE, transferred to 
nitrocellulose and stained by the peroxidase-reaction. The 
closed arrowheads indicate the four types I-IV, the open arrow 
and the asterisks indicate the complex and the degradation 
products, respectively. Lanes were loaded as follows: 
unstimulated t-PA (lane A), phorbol-ester-induced t-PA (larie 
B), commercial t-PA (American Diagnostica, lane C) and t-PA 
as in lane A after 3 cycles of freezing/thawing (lane D). Lanes 
C’ and D’ are loaded with < 10% of the material as in lanes C 
and A, respectively. 
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undetected qualitative difference in t-PA prepara- 
tions from the same cell line under the pressure of 
a biological response modifier. From fig.2 (lanes A 
and B) it is clear that type IV t-PA is undetectable 
in the culture supernatants from phorbol ester- 
treated melanoma cells, whereas in a similar un- 
treated culture this species was clearly identifiable. 
4. DISCUSSION 
Three major conclusions can be drawn from the 
present study: (i) the described purification techni- 
que (affinity and gel-filtration chromatography) 
yields t-PA preparations devoid of t-PA complex- 
ing activities and t-PA degradation products. The 
obtained product is N-terminus homogeneous and 
has a single-chain nature. (ii) The immunoblot 
analysis of purified t-PAS is at least 100 times more 
sensitive than Coomassie blue protein staining 
techniques and reveals novel species of t-PA in 
biological samples; and (iii) phorbol ester treat- 
ment of Bowes melanoma cells results in the secre- 
tion of only 3 out of 4 types of t-PA, indicating 
that physicochemically different t-PA preparations 
are obtained from the same cell line under dif- 
ferent (patho)physiological conditions. 
The immunosorbent chromatography yielded 
three major protein bands in the eluate with ap- 
parent M, values of > 200000, 85000 and 65000, 
respectively. To investigate if the two largest pro- 
tein bands also contained t-PA peptides complexed 
to other molecules (which might explain their 
binding to the affinity reagent), we performed an 
immunoblot analysis of the mixture of the eluate 
molecules. In this case, only the >200 and the 
65 kDa proteins were detectable (not shown). One 
other study describes the existence of a >200 kDa 
t-PA complex and suggests that this might be a t- 
PA-az-macroglobulin complex [39]. We have 
therefore purified this >200 kDa protein to 
homogeneity and probed it with a monoclonal an- 
tibody directed against human cua-macroglobulin i  
a radio-immuno-assay. No crz-macroglobulin an- 
tigenicity could be detected either in the unpurified 
or in the purified >200 kDa protein preparations 
(Professor F. Van Leuven, personal communica- 
tion). The nature of the 85 kDa protein, unrelated 
to t-PA, was not further investigated. 
The presence of KSCN during the gel-filtration 
chromatography seems to be crucial to separate the 
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three components of the affinity eluates. Gel filtra- 
tion in the absence of KSCN, FPLC ion exchange 
on mono Q, as well as affinity chromatography on 
arginine-Sepharose CL-4B proved to be inade- 
quate methods to purify t-PA. 
The purified material was analyzed by protein 
staining and zymographic analysis after elec- 
trophoretic separation. Urokinase was used as a 
control sample. Coomassie brilliant blue staining 
showed that t-PA migrated as two, not sharply 
delineated, protein bands, whereas u-PA could be 
visualized as one unsharp band. Renaturation of 
the separated proteins and fibrin agar overlay 
zymography could develop t-PA activity as one 
broad band, tending to lyse the polymerized fibrin 
also in the region of proteins migrating faster than 
those visualized with the direct staining technique. 
The u-PA sample developed fibrinolytic activity 
coinciding with the stainable protein, but also with 
the autocatalytic u-PA fragment of 33 kDa. 
When purified t-PA samples of different sources 
were analyzed by immunoblotting, using the 
affinity-purified polyclonal antibody, two novel 
types of t-PA were found (types III and IV). These 
constitute most probably less than 10% of the total 
amount, since they were not visualized by protein 
staining and also because they were detected as less 
intense bands by the immuno-peroxidase reaction. 
More remarkable is the observation that commer- 
cially available preparations of t-PA seem to con- 
tain t-PAS complexed to other molecules as well as 
t-PA degradation products. Such complexes were 
also observed in our preparations of t-PAS of 
lesser purity (e.g. >200 kDa complex). The obser- 
vation of more than two types of t-PA in culture 
fluids of eukaryotic cells is not restricted to the 
melanoma cell line but seems to be a universal 
characteristic of t-PAS secreted by mammalian cell 
cultures, both untransfected and transfected with 
the t-PA gene (in preparation). This implies that t- 
PA, generated by recombinant DNA technology is 
a more complex and heterogeneous mixture than 
previously thought. From earlier studies [ 13,141 it 
is clear that different types of t-PA have different 
specific activities. Purification of all types and 
detailed structural and functional analysis will be 
needed to define these differences between the 
various t-PA species. Possible explanations for the 
existence of structural and functional variants are: 
changes in glycosylation, N-terminal, C-terminal 
Volume 238, number 1 FEBS LETTERS September 1988 
or internal clipping or other posttranslational 
modifications. 
Another interesting finding of our studies is the 
observation of differences in the relative composi- 
tion of t-PAS, derived from the same cell substrate, 
but produced under different conditions. We have 
previously shown that the expression of the t-PA 
gene is enhanced in the melanoma cell line by phor- 
bol esters [13,32-341. A careful analysis of the 
genomic sequence of the t-PA gene [30] showed the 
presence of five AP-1 sites (at positions - 3321, 
-2316, 11189, 15360, and 16999, respectively). 
These sites, with the recognition sequence 
TGACTCA, are the c&acting regulatory elements 
that confer tumor promoter-mediated inducibility 
to different genes [40]. More recently it was found 
that the same consensus sequence functions as a 
recognition point of the activated jun-oncogene 
product, suggestedly identical to the transcription 
factor AP-1 [41]. The observation that after phor- 
bol ester treatment melanoma cells fail to produce 
type IV t-PA implies that such cells contain dif- 
ferently processed t-PA proteins when compared 
to untreated cells. Alternative splicing or abnormal 
termination of transcription seems not to occur, 
since no mRNAs, abnormal in size, are observed 
on Northern blot analysis. Nevertheless, the 
absence of type IV illustrates that there exists a 
physicochemical difference between uninduced 
and phorbol ester-induced t-PA preparations. 
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